

Supplementary Table 2. Cumulative glucocorticoid use in patients with AAV according to serological and clinicopathological classifications ^{1,2}

	MPO-AAV ³			PR3-AAV ⁴			p	MPA ⁵			GPA ⁶			p
	(n = 66)			(n = 131)				(n = 48)			(n = 148)			
6 months	3.90			4.10			0.60	3.90			4.10			0.86
	RTX	CYC/AZA	p	RTX	CYC/AZA	p		RTX	CYC/AZA	p	RTX	CYC/AZA	p	
	3.70	4.10	0.30	4.00	4.30	0.22		3.70	4.00	0.47	3.90	4.30	0.17	
12 months	4.00			4.30			0.33	4.00			4.30			0.50
	RTX	CYC/AZA	p	RTX	CYC/AZA	p		RTX	CYC/AZA	p	RTX	CYC/AZA	p	
	3.80	4.20	0.48	4.10	4.40	0.04		3.70	4.10	0.41	4.00	4.40	0.05	
18 months	4.00			4.60			0.10	4.00			4.50			0.19
	RTX	CYC/AZA	p	RTX	CYC/AZA	p		RTX	CYC/AZA	p	RTX	CYC/AZA	p	
	3.80	4.20	0.30	4.60	4.70	0.50		3.80	4.10	0.56	4.40	4.70	0.31	

¹ Values represent the median dose of prednisone in grams. ² One patient had an indeterminate type of AAV. ³ RTX-treated MPO-AAV patients, n = 33;

CYC/AZA-treated MPO-AAV patients, n = 33. ⁴ RTX-treated PR3-AAV patients, n = 66; CYC/AZA-treated PR3-AAV patients, n = 65. ⁵ RTX-treated MPA

patients, n = 24; CYC/AZA-treated MPA patients, n = 24. ⁶ RTX-treated GPA patients, n = 74; CYC/AZA-treated GPA patients, n = 74

AAV = ANCA-associated vasculitis; GPA = granulomatous polyangiitis; MPA = microscopic polyangiitis; RTX = rituximab; CYC = cyclophosphamide; AZA = azathioprine